ONCT - Oncternal Therapeutics Inc Stock Price, Fair Value and News

$0.530.00 (0.00%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ONCT Price Action

Last 30 days

-53.5%

Last 90 days

-63.7%

Trailing 12 Months

-92.8%

ONCT RSI Chart

ONCT Valuation

Market Cap

1.6M

Price/Earnings (Trailing)

-0.05

Price/Sales (Trailing)

0.73

EV/EBITDA

0.29

Price/Free Cashflow

-0.06

ONCT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ONCT Fundamentals

ONCT Revenue

Revenue (TTM)

2.2M

Rev. Growth (Yr)

175.98%

Rev. Growth (Qtr)

-38.33%

ONCT Earnings

Earnings (TTM)

-34.6M

Earnings Growth (Yr)

14.18%

Earnings Growth (Qtr)

1.11%

ONCT Profitability

EBT Margin

-1823.74%

Return on Equity

-377.95%

Return on Assets

-221.62%

Free Cashflow Yield

-1.7K%

ONCT Investor Care

Shares Dilution (1Y)

0.77%

Diluted EPS (TTM)

-11.68

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.2M	1.8M	2.2M	0
2023	947.0K	862.0K	659.0K	785.0K
2022	4.3M	3.6M	1.9M	1.5M
2021	3.5M	3.8M	5.3M	4.3M
2020	2.5M	2.5M	2.5M	3.4M
2019	2.8M	1.9M	2.2M	2.4M
2018	0	5.4M	3.7M	4.2M
2012	5.5M	0	0	0
2011	45.5M	34.3M	23.0M	11.7M
2010	0	28.7M	42.8M	56.8M
2009	0	0	0	14.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Oncternal Therapeutics Inc

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

CEO	Dr. James B. Breitmeyer M.D., Ph.D.
WEBSITE	oncternal.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	30

Oncternal Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Oncternal Therapeutics Inc? What does ONCT stand for in stocks?

ONCT is the stock ticker symbol of Oncternal Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Oncternal Therapeutics Inc (ONCT)?

As of Thu Dec 19 2024, market cap of Oncternal Therapeutics Inc is 1.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ONCT stock?

You can check ONCT's fair value in chart for subscribers.

Is Oncternal Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ONCT is over valued or under valued. Whether Oncternal Therapeutics Inc is cheap or expensive depends on the assumptions which impact Oncternal Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ONCT.

What is Oncternal Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 19 2024, ONCT's PE ratio (Price to Earnings) is -0.05 and Price to Sales (PS) ratio is 0.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ONCT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Oncternal Therapeutics Inc's stock?

In the past 10 years, Oncternal Therapeutics Inc has provided -0.539 (multiply by 100 for percentage) rate of return.